Let's get the headline out of the way: capital is available. Across the stack—equity, mezzanine, structured—there's no shortage of dry powder looking for a home. Family offices continue to proliferate. Alternative capital sources have multiplied. The independent sponsor model has gone from a niche curiosity to a recognized institutional channel.
So why does raising capital still feel like pushing a boulder uphill?
Because having capital available and having capital committed to your deal are two entirely different things. The constraint isn't money. It's the supply of deals that capital providers actually want to fund. And the bar for what qualifies as a "high-quality deal" has moved materially higher over the past two years.
The sponsors who are closing deals efficiently in this market share a common trait: they started building relationships with capital partners long before they had a live transaction to fund.
This sounds obvious. It isn't how most independent sponsors operate. The typical pattern is to find a deal, scramble to assemble capital, and pitch cold or lukewarm relationships under time pressure. It works occasionally. It works less and less in a market where capital providers have more options, more deal flow, and more reasons to say no.
The better approach—and this is true whether you're investing in healthcare, business services, or industrial distribution—is sustained, low-pressure engagement with capital partners between deals. Periodic updates on what you're seeing in your target sectors. Honest assessments of deals you looked at and passed on, and why. Sharing your investment thesis as it evolves. This isn't networking. It's building the kind of credibility that means when you do call with a live deal, the conversation starts at a different level.
In healthcare specifically, this matters even more. Capital partners who don't live in the sector need to trust that you understand the regulatory dynamics, the reimbursement shifts, and the operational complexity that can turn a promising platform into an expensive lesson. If you're raising capital for a behavioral health roll-up and your partners first learn about CMS reimbursement changes or v28 risk adjustment headwinds during diligence, you've already lost momentum. Or more likely, you receive their “polite pass.”
"We invest in healthcare services" is not an investment thesis. It's meant to sound like a deep stake in the ground—a declaration of focus and expertise. But capital providers hear some version of this dozens of times a quarter, and when they press on it, the depth usually isn't there. The sponsor has read the industry reports, maybe attended a conference or two, but can't speak to how reimbursement actually flows through a value-based care model, what happens to margins when a state redetermines Medicaid eligibility, or why the same roll-up playbook that works in outpatient mental health falls apart in addiction treatment. Claiming a sector focus and actually having one are different things, and experienced capital partners can tell the difference in about ten minutes.
A credible thesis in healthcare today requires specificity. Which sub-sector and why now? What structural tailwind are you capturing—and can you articulate what happens to that tailwind if reimbursement policy shifts, payer dynamics change, or workforce economics deteriorate? If you're targeting outpatient behavioral health, do you understand why autism platforms command 12–15 times EBITDA while addiction treatment facilities trade at 5 times? If you're looking at value-based primary care in Medicare Advantage, can you explain what v28 did to the economics and why some platforms are thriving while others are reverting to fee-for-service?
The sponsors who differentiate themselves have done the industry mapping, built relationships with operators and intermediaries in their target sectors, and can walk a capital partner through the competitive landscape with the fluency of someone who's been studying it for years—because they have been. They know which deals are coming to market before the books go out. They have a point of view on valuation that's informed by comparable transactions, not just a multiple range pulled from a pitch deck.
This is the work that most sponsors skip because it doesn't feel urgent until they're sitting across from a capital partner who asks a question they can't answer.
I've spent three decades on the advisory side of healthcare transactions, and I can tell you what kills deals faster than anything: complexity that wasn't disclosed early and risk that wasn't framed honestly.
Capital providers favor transactions that are straightforward, transparent, and strategically sound. They want strong industry tailwinds, simple business models, and clearly articulated value creation plans. None of that is surprising. What separates the sponsors who close from those who don't is the willingness to proactively surface the risks—and have a credible plan for each one.
In healthcare, the risk landscape is specific and non-trivial. Regulatory exposure, payer concentration, clinician retention, Medicaid uncertainty, licensure complexity across states—these aren't generic risk factors you can wave away with a sensitivity table. They're operational realities that determine whether a platform scales or stalls. The sponsors who earn trust are the ones who say, "Here's what keeps me up at night about this deal, and here's specifically how we mitigate it." That kind of transparency isn't weakness. It's the single most effective credibility-building tool you have in a capital raise.
This is where I've watched more independent sponsor deals go sideways than almost anywhere else: structuring decisions that get locked in at the letter of intent stage and become nearly impossible to unwind later.
Seller rollover percentages that look less like alignment and more like a polite bail by the founder. Earn-out mechanics that aren't tied to real growth milestones. Purchase price holdbacks that were cut and pasted from a template two years off market. Management equity pools sized without any conversation about who's actually staying and in what capacity. These aren't details to negotiate after you've signed—they're foundational elements that shape how your capital partners evaluate the deal and, frankly, how they evaluate you. Engaging your equity partners before the LOI allows you to pressure-test structure and pricing, align expectations on governance and exit timing, and avoid the painful mid-process renegotiations that erode trust with sellers and capital partners simultaneously.
In healthcare transactions specifically, there are additional structural considerations that experienced sponsors plan for early: regulatory approval timelines, licensure transfer requirements, change-of-control provisions in payer contracts, and the operational continuity planning that ensures clinical operations don't degrade during the transition. First-time sellers in healthcare—and there are many in the fragmented sub-sectors where independent sponsors tend to operate—often underestimate the complexity and timeline of these processes. When that happens, the sponsor pays the price for the seller's misperception and poor planning. Not the seller. Not the intermediary. The sponsor. The one who anticipated this and built it into the deal schedule from the start is the one who actually closes.
Independent sponsor transactions are inherently messier than traditional PE deals. You're often working with founder-operators selling a business for the first time, advised by a local attorney or regional intermediary who may not have deep M&A experience. The quality of information in the data room varies. Financial reporting may not be audited. The seller's expectations on valuation, timeline, and post-close involvement may be disconnected from market reality.
None of this is disqualifying. But it requires a sponsor who builds flexibility into timelines, manages expectations early and often, and sequences diligence and legal work with the kind of discipline that prevents cost overruns and blown deadlines. CRM tools for tracking outreach, staged capital raises with clear milestones, and rigorous process management aren't glamorous—but they're the difference between a deal that closes in 90 days and one that dies at month six because everyone ran out of patience.
Here's what three decades in healthcare deal advisory has taught me about capital raising: the sponsors who consistently close aren't the ones with the slickest decks or the most impressive pedigrees. They're the ones who've done the work before the work starts. They've built relationships when there was nothing to sell. They've developed a thesis grounded in genuine expertise, not borrowed conviction. They've structured deals with the end in mind. And they've treated every capital partner interaction as an opportunity to build trust rather than extract a commitment.
Capital is available in 2026. Competition for quality deals has intensified. The sponsors who win will be the ones who've earned the right to be taken seriously—not by talking about their pipeline, but by demonstrating the preparation, credibility, and execution discipline that makes capital providers want to be part of what they're building.
The money follows the conviction. Always has.
